1Wayne State University School of Medicine, Detroit, MI
2University of Iowa Hospitals, Iowa City, IA [email protected]
Dr. Lieberman reports receiving consulting fees and lecture fees from Medtronic and consulting fees from Aziyo Biologics; and Dr. Olshansky, serving as national co-chair of the Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) trial for Boehringer Ingelheim, serving as chair of the data and safety monitoring board of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) for Amarin Pharma, receiving speaking and consulting fees from Lundbeck, and receiving consulting fees from Respironics. No other potential conflict of interest relevant to this letter was reported.
